(Q30250250)

13 June 2017

1 reference

1 reference

title

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper (English)

1 reference

domain-ontology-based fuzzy-powered named-entity recognition matcher

13 June 2017

1 reference

1 reference

1 reference

1 reference

Neurology

5 February 2022

author

Per Soelberg Sørensen

5

object named as

Per Soelberg Sørensen

1 reference

13 June 2017

Alan J Thompson

6

0 references

Hans-Peter Hartung

4

object named as

Hans-Peter Hartung

1 reference

13 June 2017

3

Giancarlo Comi

1 reference

13 June 2017

8

Ralf Gold

1 reference

13 June 2017

Susana Otero-Romero

1

1 reference

13 June 2017

Jaume Sastre-Garriga

2

1 reference

13 June 2017

Patrick Vermersch

7

1 reference

13 June 2017

Xavier Montalban

9

1 reference

13 June 2017

publication date

19 May 2016

1 reference

Multiple Sclerosis Journal

13 June 2017

published in

1 reference

13 June 2017

volume

22

1 reference

13 June 2017

issue

11

1 reference

13 June 2017

page(s)

1386-1396

1 reference

Prevalence and treatment of spasticity reported by multiple sclerosis patients

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Spasticity-assessment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A systematic review of the Tardieu Scale for the measurement of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Clinical assessment of spasticity in spinal cord injury: a multidimensional problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Quantifying repeatability of the Wartenberg pendulum test parameters in children with spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Clinical management of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Non pharmacological interventions for spasticity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A comparison of baclofen and diazepam in the treatment of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Baclofen for spasticity in multiple sclerosis Double-blind crossover and three-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Baclofen in the Treatment of Spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A benefit-risk assessment of baclofen in severe spinal spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Epilepsy, psychosis, and schizophrenia: clinical and neuropathologic correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Comparison of dantrolene sodium and diazepam in the treatment of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Drugs used to treat spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Gabapentin for relief of spasticity associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Treatment of Spasticity in Multiple Sclerosis With Dantrolene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Role of cannabinoids in the treatment of pain and (painful) spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Stop using the Ashworth Scale for the assessment of spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Adverse effects of medical cannabinoids: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Management of spasticity in adults: practical application of botulinum toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Treatment of spasticity with botulinum toxin: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

The use of phenol as a neurolytic agent: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

The use of intrathecal phenol for muscle spasms in multiple sclerosis. A description of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

Intrathecal phenol: an old treatment revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516643600

21 January 2018

Identifiers

DOI

10.1177/1352458516643600

1 reference

13 June 2017

1 reference